Filing Flows › 4D Molecular Therapeutics (FDMT) › Q1 2026 › vs Q4 2025
4D Molecular Therapeutics (FDMT) Q1 2026 vs Q4 2025 (quarter over quarter)
4D Molecular Therapeutics's revenue fell $82.0M (-96%) from $85.1M in Q4 2025 to $3.0M in Q1 2026.
4D Molecular Therapeutics, Q1 2026: revenue $3.0M (218× year over year), net loss $68.8M, operating cash flow −$68.1M. The chart draws each line against Q4 2025, the increases inside each band.
Every line
| Line | Q1 2026 | Q4 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $3.0M | $85.1M | −$82.0M | -96% |
| Other income, net | $4.9M | $4.7M | $178K | +4% |
| Net loss | $68.8M | −$19.4M | $88.2M | — |
| Costs & expenses | $76.7M | $89.8M | −$13.1M | -15% |
| Operating costs | $76.7M | $70.4M | $6.3M | +9% |
| Research & development | $65.0M | $57.6M | $7.4M | +13% |
| General & admin | $11.7M | $12.8M | −$1.1M | -8% |
| Operating cash sources | $73.8M | −$21.8M | $95.6M | — |
| Depreciation & amortization | $1.3M | $1.2M | $53K | +4% |
| Share-based compensation | $4.5M | $5.6M | −$1.1M | -20% |
| Cash used in operations | $68.1M | −$28.6M | $96.7M | — |
| Net loss absorbed | $68.8M | −$19.4M | $88.2M | — |
| Working capital & other | $5.1M | −$2.4M | $7.5M | — |
Questions
How much did 4D Molecular Therapeutics's revenue grow quarter over quarter in Q1 2026?
4D Molecular Therapeutics's revenue fell $82.0M (-96%) from $85.1M in Q4 2025 to $3.0M in Q1 2026.